GLP-1 Clinical Relevance #49Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Meta-AnalysisRandomized Controlled TrialObesity TreatmentSemaglutideLiraglutideGLP-1 Receptor AgonistEndocrinologyAdults with ObesityLean Mass PreservationMuscle Loss RiskBody...
“Over 70% Of Studies Back Medical Cannabis In Cancer Treatment” “A sweeping meta …
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic OncologyPain ManagementNauseaAppetiteMeta-Analysis Why This MattersMeta-analyses of cannabis in oncology provide the strongest level of...
Cannabinoid Clinical Trials: Anxiety & Tourette Review
Clinical Takeaway Cannabinoid formulations, including CBD and THC-containing products, show measurable reductions in anxiety symptoms across multiple disorder types, based on pooled data from randomized and observational studies. Evidence supports modest but...
GLP-1 Receptor Agonist Evidence: 20% Heart Attack Risk Drop
GLP-1 Clinical Relevance #51Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic GLP-1 Cardiovascular BenefitsMedicare GLP-1 CoverageOzempic Heart ProtectionSemaglutide Clinical DataWegovy Medicare Access Why...
Cannabis and Schizophrenia: Meta-Analysis Finds Roughly Threefold Risk Elevation, but Causation Remains Contested
Cannabinoids likely contribute to chronic psychotic events and schizophrenia, especially if taken during adolescence. This effect likely increases with a high cannabis THC concentration and increased frequency of cannabis use, and is stronger in males than in females.
Cannabis Users Need More Propofol, But Confounders Cloud the Evidence
Propofol requirements were significantly higher in cannabis users, who required an average additional dose of 47.33 mg compared to non-users. Subgroup analyses revealed that cannabis users undergoing general anesthesia needed an additional 30.57 mg intraoperatively, while those undergoing sedation for endoscopic procedures required an additional 53.02 mg.
Cannabinoids for Postoperative Pain: A Systematic Review Finds Too Little Evidence to Draw Firm Conclusions
Due to the heterogeneity of methods, it was not possible to carry out meta-analytic evaluations and only qualitative evaluations were feasible.
What the Evidence Actually Says About Cannabis: Risks, Benefits, and Lingering Uncertainties
“Chronic patterns of cannabis use have been associated with multiple adverse outcomes that are of particular concern among adolescents and young adults, such as, disrupted learning, impaired cognitive performance, reduced educational attainment and an increased risk of CUD, psychosis/schizophrenia, mood and anxiety disorders and suicidal behaviors. There is debate about the extent to which cannabis use is a cause of these adverse outcomes.”
Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.
Substance use disorder (SUD) is commonly found in individuals with schizophrenia, with a high co-occurrence rate of approximately 41.7%. Despite this high pr…
Cannabis and Sleep Review, Read Carefully
This paper is a systematic review and meta-analysis on recreational cannabis use and sleep in the general population. It brings together observational and experimental studies and finds that poorer sleep outcomes appear more often in observational data than in controlled trials. That makes the paper useful for counseling and evidence literacy, but not strong enough to prove that recreational cannabis directly worsens or improves sleep across settings.